Blepharospasm Clinical Trial
Official title:
The Effect of Zinc Supplementation on the Efficacy and Duration of Botulinum Toxin for the Treatment of Oculofacial Spasm Disorders
The purpose of this study is to determine whether zinc supplements are effective in enhancing the treatment of oculofacial spasm disorders with botulinum toxin.
Botulinum Toxin (Botox) has been used for many years in the treatment of oculofacial dystonias such as blepharospasm and hemifacial spasm. It has also gained widespread use for cosmetic purposes. The efficacy and duration of its effect is not constant amongst all patients. Some patient respond very well, while others have no clinical benefit or the clinical benefit does not last as long as expected. Zinc is known to be an important co-factor in the molecular effects of Botox. The investigators hypothesize that one of the many factors that may contribute to the variability in the response to Botox may be the level of Zinc available within the neuromuscular junction of those patients. The investigators plan to to test whether or not giving patients supplemental Zinc with their Botox injections would help improve the magnitude and duration of the intended clinical effect. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01686061 -
Blepharospasm Patient Survey for Patients With Blepharospasm
|
||
| Completed |
NCT00535938 -
MDs on Botox Utility (MOBILITY)
|
N/A | |
| Recruiting |
NCT05027997 -
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
|
Phase 2 | |
| Terminated |
NCT03263000 -
Photic Blink Reflex in People With Blepharospasm and Increased Blinking
|
||
| Completed |
NCT03938363 -
Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia
|
N/A | |
| Completed |
NCT02947815 -
Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
|
Phase 2/Phase 3 | |
| Completed |
NCT00406367 -
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
|
Phase 3 | |
| Completed |
NCT00682760 -
Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm
|
Phase 3 | |
| Completed |
NCT00210431 -
Post Marketing Surveillance Study of Dysport
|
||
| Completed |
NCT05103202 -
Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
|
||
| Completed |
NCT04423341 -
Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm
|
Phase 2/Phase 3 | |
| Completed |
NCT03269123 -
A Mechanical Device for Blepharospasm
|
N/A | |
| Completed |
NCT00411255 -
Brain Stimulation to Treat Blepharospasm or Meige Syndrome
|
Phase 2 | |
| Completed |
NCT00500799 -
Brain Changes in Blepharospasm
|
N/A | |
| Completed |
NCT00761592 -
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
|
Phase 4 | |
| Completed |
NCT00001784 -
Mexiletine for the Treatment of Focal Dystonia
|
Phase 2 | |
| Recruiting |
NCT04939909 -
Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm
|
Early Phase 1 | |
| Completed |
NCT03508882 -
Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm
|
Phase 4 | |
| Completed |
NCT01814774 -
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
|
N/A | |
| Completed |
NCT00234507 -
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
|
Phase 2 |